Literature DB >> 18515173

Crosstalk via the NF-kappaB signaling system.

Soumen Basak1, Alexander Hoffmann.   

Abstract

The nuclear factor kappaB (NF-kappaB) family of transcription factors consists of 15 possible dimers whose activity is controlled by a family of inhibitor proteins, known as IkappaBs. A variety of cellular stimuli, many of them transduced by members of the tumor necrosis factor receptor (TNFR) superfamily, induce degradation of IkappaBs to activate an overlapping subset of NF-kappaB dimers. However, generation and stimulus-responsive activation of NF-kappaB dimers are intimately linked via various cross-regulatory mechanisms that allow crosstalk between different signaling pathways through the NF-kappaB signaling system. In this review, we summarize these mechanisms and discuss physiological and pathological consequences of crosstalk between apparently distinct inflammatory and developmental signals. We argue that a systems approach will be valuable for understanding questions of specificity and emergent properties of highly networked cellular signaling systems.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515173      PMCID: PMC2675004          DOI: 10.1016/j.cytogfr.2008.04.005

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  63 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Purified human I kappa B can rapidly dissociate the complex of the NF-kappa B transcription factor with its cognate DNA.

Authors:  U Zabel; P A Baeuerle
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

3.  NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100.

Authors:  G Xiao; E W Harhaj; S C Sun
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

4.  Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment.

Authors:  E Alcamo; J P Mizgerd; B H Horwitz; R Bronson; A A Beg; M Scott; C M Doerschuk; R O Hynes; D Baltimore
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

5.  Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B.

Authors:  J A DiDonato; F Mercurio; M Karin
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

6.  Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice.

Authors:  L Yin; L Wu; H Wesche; C D Arthur; J M White; D V Goeddel; R D Schreiber
Journal:  Science       Date:  2001-03-16       Impact factor: 47.728

7.  Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines.

Authors:  D S Weih; Z B Yilmaz; F Weih
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

8.  Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.

Authors:  Y H Zhang; A Heulsmann; M M Tondravi; A Mukherjee; Y Abu-Amer
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

9.  Generation and activation of multiple dimeric transcription factors within the NF-kappaB signaling system.

Authors:  Soumen Basak; Vincent Feng-Sheng Shih; Alexander Hoffmann
Journal:  Mol Cell Biol       Date:  2008-02-25       Impact factor: 4.272

10.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B.

Authors:  A A Beg; W C Sha; R T Bronson; S Ghosh; D Baltimore
Journal:  Nature       Date:  1995-07-13       Impact factor: 49.962

View more
  68 in total

1.  Classical NF-kappaB activation negatively regulates noncanonical NF-kappaB-dependent CXCL12 expression.

Authors:  Lisa A Madge; Michael J May
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 2.  Nuclear initiated NF-κB signaling: NEMO and ATM take center stage.

Authors:  Shigeki Miyamoto
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

Review 3.  Targeting innate immunity protein kinase signalling in inflammation.

Authors:  Matthias Gaestel; Alexey Kotlyarov; Michael Kracht
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 4.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

Review 5.  The regulatory logic of the NF-kappaB signaling system.

Authors:  Ellen O'Dea; Alexander Hoffmann
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

Review 6.  Current concepts on the role of nitric oxide in portal hypertension.

Authors:  Liang Shuo Hu; Jacob George; Jian Hua Wang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

7.  Medium-chain triglyceride ameliorates insulin resistance and inflammation in high fat diet-induced obese mice.

Authors:  Shanshan Geng; Weiwei Zhu; Chunfeng Xie; Xiaoting Li; Jieshu Wu; Zhaofeng Liang; Wei Xie; Jianyun Zhu; Cong Huang; Mingming Zhu; Rui Wu; Caiyun Zhong
Journal:  Eur J Nutr       Date:  2015-04-25       Impact factor: 5.614

Review 8.  A new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-kappaB family.

Authors:  Christoph F A Vogel; Fumio Matsumura
Journal:  Biochem Pharmacol       Date:  2008-10-08       Impact factor: 5.858

9.  Integrative analysis suggests cell type-specific decoding of NF-κB dynamics.

Authors:  Erik W Martin; Alicja Pacholewska; Heta Patel; Himanshu Dashora; Myong-Hee Sung
Journal:  Sci Signal       Date:  2020-02-25       Impact factor: 8.192

10.  Principles of modular tumor therapy.

Authors:  Albrecht Reichle; Gerhard C Hildebrandt
Journal:  Cancer Microenviron       Date:  2009-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.